ADMA BIOLOGICS INC (ADMA) Stock Fundamental Analysis
USA - NASDAQ:ADMA - US0008991046 - Common Stock
14.52 USD
+0.49 (+3.49%)
14.18 USD
-0.34 (-2.34%)
Overall ADMA gets a fundamental rating of 6 out of 10. We evaluated ADMA against 534 industry peers in the Biotechnology industry. ADMA is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. ADMA is evaluated to be cheap and growing strongly. This does not happen too often! These ratings could make ADMA a good candidate for value and growth investing.
1. Profitability
1.1 Basic Checks
ADMA had positive earnings in the past year.
In the past year ADMA had a positive cash flow from operations.
In the past 5 years ADMA reported 4 times negative net income.
In multiple years ADMA reported negative operating cash flow during the last 5 years.
1.2 Ratios
The Return On Assets of ADMA (37.42%) is better than 99.06% of its industry peers.
Looking at the Return On Equity, with a value of 52.45%, ADMA belongs to the top of the industry, outperforming 98.69% of the companies in the same industry.
The Return On Invested Capital of ADMA (25.43%) is better than 98.50% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 37.42% | ||
| ROE | 52.45% | ||
| ROIC | 25.43% |
ROA(3y)4.32%
ROA(5y)-9.88%
ROE(3y)-2.53%
ROE(5y)-28.83%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ADMA has a better Profit Margin (44.06%) than 98.69% of its industry peers.
With an excellent Operating Margin value of 32.82%, ADMA belongs to the best of the industry, outperforming 97.19% of the companies in the same industry.
Looking at the Gross Margin, with a value of 53.00%, ADMA is in the better half of the industry, outperforming 76.03% of the companies in the same industry.
In the last couple of years the Gross Margin of ADMA has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 32.82% | ||
| PM (TTM) | 44.06% | ||
| GM | 53% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y226.2%
GM growth 5YN/A
2. Health
2.1 Basic Checks
ADMA has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for ADMA has been increased compared to 1 year ago.
ADMA has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, ADMA has an improved debt to assets ratio.
2.2 Solvency
ADMA has an Altman-Z score of 14.40. This indicates that ADMA is financially healthy and has little risk of bankruptcy at the moment.
ADMA has a Altman-Z score of 14.40. This is amongst the best in the industry. ADMA outperforms 87.08% of its industry peers.
ADMA has a debt to FCF ratio of 1.12. This is a very positive value and a sign of high solvency as it would only need 1.12 years to pay back of all of its debts.
ADMA's Debt to FCF ratio of 1.12 is amongst the best of the industry. ADMA outperforms 94.01% of its industry peers.
A Debt/Equity ratio of 0.18 indicates that ADMA is not too dependend on debt financing.
ADMA has a Debt to Equity ratio of 0.18. This is in the lower half of the industry: ADMA underperforms 67.79% of its industry peers.
Even though the debt/equity ratio score it not favorable for ADMA, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 1.12 | ||
| Altman-Z | 14.4 |
ROIC/WACC2.91
WACC8.74%
2.3 Liquidity
ADMA has a Current Ratio of 5.33. This indicates that ADMA is financially healthy and has no problem in meeting its short term obligations.
ADMA's Current ratio of 5.33 is in line compared to the rest of the industry. ADMA outperforms 58.43% of its industry peers.
A Quick Ratio of 2.78 indicates that ADMA has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.78, ADMA is doing worse than 64.42% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.33 | ||
| Quick Ratio | 2.78 |
3. Growth
3.1 Past
ADMA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 96.43%, which is quite impressive.
Looking at the last year, ADMA shows a very strong growth in Revenue. The Revenue has grown by 65.15%.
The Revenue has been growing by 70.84% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)96.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%6.67%
Revenue 1Y (TTM)65.15%
Revenue growth 3Y74.04%
Revenue growth 5Y70.84%
Sales Q2Q%12%
3.2 Future
The Earnings Per Share is expected to grow by 32.01% on average over the next years. This is a very strong growth
Based on estimates for the next years, ADMA will show a very strong growth in Revenue. The Revenue will grow by 20.94% on average per year.
EPS Next Y21.04%
EPS Next 2Y37.55%
EPS Next 3Y35.8%
EPS Next 5Y32.01%
Revenue Next Year19.81%
Revenue Next 2Y22.86%
Revenue Next 3Y24.53%
Revenue Next 5Y20.94%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 26.40, ADMA can be considered very expensive at the moment.
ADMA's Price/Earnings ratio is rather cheap when compared to the industry. ADMA is cheaper than 94.01% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 25.83. ADMA is around the same levels.
ADMA is valuated correctly with a Price/Forward Earnings ratio of 15.35.
ADMA's Price/Forward Earnings ratio is rather cheap when compared to the industry. ADMA is cheaper than 94.94% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of ADMA to the average of the S&P500 Index (32.68), we can say ADMA is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 26.4 | ||
| Fwd PE | 15.35 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ADMA is valued cheaply inside the industry as 93.63% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, ADMA is valued cheaper than 92.51% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 52.81 | ||
| EV/EBITDA | 20.37 |
4.3 Compensation for Growth
ADMA's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
ADMA has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as ADMA's earnings are expected to grow with 35.80% in the coming years.
PEG (NY)1.25
PEG (5Y)N/A
EPS Next 2Y37.55%
EPS Next 3Y35.8%
5. Dividend
5.1 Amount
No dividends for ADMA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
14.52
+0.49 (+3.49%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners89.29%
Inst Owner Change-3.38%
Ins Owners2.35%
Ins Owner Change-0.83%
Market Cap3.46B
Revenue(TTM)426.45M
Net Income(TTM)208.93M
Analysts84
Price Target27.8 (91.46%)
Short Float %7.67%
Short Ratio5.4
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-16.56%
Min EPS beat(2)-31.17%
Max EPS beat(2)-1.96%
EPS beat(4)1
Avg EPS beat(4)-7.13%
Min EPS beat(4)-31.17%
Max EPS beat(4)13.12%
EPS beat(8)4
Avg EPS beat(8)-13.7%
EPS beat(12)6
Avg EPS beat(12)-7.65%
EPS beat(16)9
Avg EPS beat(16)-4.75%
Revenue beat(2)0
Avg Revenue beat(2)-2.91%
Min Revenue beat(2)-3.31%
Max Revenue beat(2)-2.51%
Revenue beat(4)2
Avg Revenue beat(4)1.84%
Min Revenue beat(4)-3.31%
Max Revenue beat(4)10.99%
Revenue beat(8)6
Avg Revenue beat(8)4.93%
Revenue beat(12)10
Avg Revenue beat(12)6.13%
Revenue beat(16)14
Avg Revenue beat(16)6.66%
PT rev (1m)-6.23%
PT rev (3m)-7.6%
EPS NQ rev (1m)-2.17%
EPS NQ rev (3m)-10%
EPS NY rev (1m)0%
EPS NY rev (3m)-6.59%
Revenue NQ rev (1m)-0.51%
Revenue NQ rev (3m)0.02%
Revenue NY rev (1m)-0.08%
Revenue NY rev (3m)-0.03%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 26.4 | ||
| Fwd PE | 15.35 | ||
| P/S | 7.31 | ||
| P/FCF | 52.81 | ||
| P/OCF | 45.17 | ||
| P/B | 8.7 | ||
| P/tB | 8.79 | ||
| EV/EBITDA | 20.37 |
EPS(TTM)0.55
EY3.79%
EPS(NY)0.95
Fwd EY6.52%
FCF(TTM)0.27
FCFY1.89%
OCF(TTM)0.32
OCFY2.21%
SpS1.99
BVpS1.67
TBVpS1.65
PEG (NY)1.25
PEG (5Y)N/A
Graham Number4.54
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 37.42% | ||
| ROE | 52.45% | ||
| ROCE | 32.19% | ||
| ROIC | 25.43% | ||
| ROICexc | 31.27% | ||
| ROICexgc | 31.6% | ||
| OM | 32.82% | ||
| PM (TTM) | 44.06% | ||
| GM | 53% | ||
| FCFM | 13.84% |
ROA(3y)4.32%
ROA(5y)-9.88%
ROE(3y)-2.53%
ROE(5y)-28.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y226.2%
GM growth 5YN/A
F-Score5
Asset Turnover0.85
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 1.12 | ||
| Debt/EBITDA | 0.45 | ||
| Cap/Depr | 140.25% | ||
| Cap/Sales | 2.34% | ||
| Interest Coverage | 13.21 | ||
| Cash Conversion | 46.9% | ||
| Profit Quality | 31.4% | ||
| Current Ratio | 5.33 | ||
| Quick Ratio | 2.78 | ||
| Altman-Z | 14.4 |
F-Score5
WACC8.74%
ROIC/WACC2.91
Cap/Depr(3y)120.67%
Cap/Depr(5y)186.15%
Cap/Sales(3y)4.32%
Cap/Sales(5y)11.97%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)96.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%6.67%
EPS Next Y21.04%
EPS Next 2Y37.55%
EPS Next 3Y35.8%
EPS Next 5Y32.01%
Revenue 1Y (TTM)65.15%
Revenue growth 3Y74.04%
Revenue growth 5Y70.84%
Sales Q2Q%12%
Revenue Next Year19.81%
Revenue Next 2Y22.86%
Revenue Next 3Y24.53%
Revenue Next 5Y20.94%
EBIT growth 1Y85.41%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year49.25%
EBIT Next 3Y41.34%
EBIT Next 5Y36.11%
FCF growth 1Y227.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y285.06%
OCF growth 3YN/A
OCF growth 5YN/A
ADMA BIOLOGICS INC / ADMA FAQ
What is the fundamental rating for ADMA stock?
ChartMill assigns a fundamental rating of 6 / 10 to ADMA.
Can you provide the valuation status for ADMA BIOLOGICS INC?
ChartMill assigns a valuation rating of 7 / 10 to ADMA BIOLOGICS INC (ADMA). This can be considered as Undervalued.
How profitable is ADMA BIOLOGICS INC (ADMA) stock?
ADMA BIOLOGICS INC (ADMA) has a profitability rating of 6 / 10.
What are the PE and PB ratios of ADMA BIOLOGICS INC (ADMA) stock?
The Price/Earnings (PE) ratio for ADMA BIOLOGICS INC (ADMA) is 26.4 and the Price/Book (PB) ratio is 8.7.
Can you provide the financial health for ADMA stock?
The financial health rating of ADMA BIOLOGICS INC (ADMA) is 7 / 10.